Viracta Therapeutics’ (VIRX) “Neutral” Rating Reiterated at Rodman & Renshaw

Posted by Kyle Jackson on Dec 30th, 2024

Rodman & Renshaw reissued their neutral rating on shares of Viracta Therapeutics (NASDAQ:VIRX – Free Report) in a research note released on Friday,Benzinga reports. Rodman & Renshaw currently has a $0.25 price target on the stock, down from their prior price target of $3.50.

Separately, Royal Bank of Canada decreased their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.05.

Check Out Our Latest Stock Analysis on VIRX

Viracta Therapeutics Price Performance

VIRX stock opened at $0.16 on Friday. The firm has a market cap of $6.36 million, a PE ratio of -0.15 and a beta of 0.67. Viracta Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.31. The firm has a 50 day simple moving average of $0.19 and a 200 day simple moving average of $0.31.

Hedge Funds Weigh In On Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned about 1.27% of Viracta Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Viracta Therapeutics

(Get Free Report)

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.